email article Hormonal therapies combined with chemotherapy significantly improved radiographic progression-free survival (rPFS) for men with de novo metastatic castration-sensitive prostate cancer (mCSPC), results from a phase III study showed. In the PEACE-1 trial, the triplet therapy of abiraterone (Zytiga) plus androgen-deprivation therapy (ADT) and docetaxel extended rPFS by a median 2.5 years for these patients, and could be practice changing, reported Karim Fizazi, MD, PhD, of Institut Gustave Roussy in Villejuif, France. "Regardless of overall survival [OS] results, this data question whether we should deny patients approximately 2 and a half years without radiographic progression or death, or whether combining ADT/docetaxel and abiraterone/prednisone should simply become the new standard of care," Fizazi said during a presentation at the virtual American Society of Clinical Oncology annual meeting.